Windward Bio launched on the public markets after securing a $175 million IPO, starting trading under the ticker “WWB.” The Swiss immune-drug developer is advancing WIN378, an ultra-long-acting TSLP-targeted injectable designed for dosing as infrequently as twice per year. Interim Phase 2/3 asthma data reported by the company show WIN378 was well tolerated and improved lung function measures linked to airway inflammation, including changes in exhaled air and eosinophil depletion. Phase 3 in asthma is already underway, and a COPD study is in progress. The offering also signals investor appetite for cytokine-axis programs beyond traditional IL-4/IL-13 and anti-IgE approaches, particularly where dosing frequency and durability are positioned as differentiators.